(2S,4Ξ)-2-amino-4-methyl-glutaramic acid | 38520-42-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4Ξ)-2-amino-4-methyl-glutaramic acid
• 英文别名: (2S,4Ξ)-2-Amino-4-methyl-glutaramidsaeure；4-Methyl-L-glutamine；(2S)-2,5-diamino-4-methyl-5-oxopentanoic acid
• CAS: 38520-42-2
• 化学式: C₆H₁₂N₂O₃
• 分子量: 160.173
• InChiKey: YWSYZEMJPFOFKY-BKLSDQPFSA-N

物化性质

• 沸点：
  426.6±40.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4Ξ)-2-amino-4-methyl-glutaramic acid 在 盐酸 作用下， 生成 (2S)-4-methylglutamic acid
  参考文献：
  名称：

  Meister, Journal of Biological Chemistry, 1954, vol. 210, p. 17,21

  摘要：

  DOI：
• 作为产物：
  描述：

  optically inactive 2-benzyloxycarbonylamino-4-methyl-glutaric acid diamide 在 papain 作用下， 生成 (2S,4Ξ)-2-amino-4-methyl-glutaramic acid
  参考文献：
  名称：

  Meister, Journal of Biological Chemistry, 1954, vol. 210, p. 17,21

  摘要：

  DOI：

文献信息

• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• Cell detection, capture and isolation methods and apparatus
  申请人：Axon Dx, LLC

  公开号：US10147180B2

  公开（公告）日：2018-12-04

  An optical system is provided for clinical diagnostics that include methods and apparatus for rapidly detecting and characterizing rare circulating cells such as, but not limited to, circulating tumor cells/circulating stems cells (CTC/CSCs) in a biological sample. The sample is processed for analyses, loaded onto a “capture zone” in the optical system where, and subjected to a two stage optical process for very rapid detection and detailed characterization of detected cells. The detected rare cells are characterized with regards to biomarker profiles using fluorescent tags or chromophores for detection and optical imaging. Isolation of the captured rare cells is anticipated for down-stream assessments including, but not limited to, DNA, RNA, proteomic analyses and culture.

  提供了一种用于临床诊断的光学系统，包括快速检测和表征生物样本中罕见循环细胞（如但不限于循环肿瘤细胞/循环干细胞（CTC/CSCs））的方法和装置。样本经处理后进行分析，装载到光学系统中的 "捕获区 "上，并经过两阶段光学处理，以非常快速地检测和详细鉴定检测到的细胞。利用荧光标签或发色团进行检测和光学成像，对检测到的稀有细胞进行生物标记特征描述。预计将对捕获的稀有细胞进行分离，以便进行下游评估，包括但不限于 DNA、RNA、蛋白质组分析和培养。
• Microparticles with an improved release profile and method for the production thereof
  申请人：——

  公开号：US20040115277A1

  公开（公告）日：2004-06-17

  The present invention relates to microparticles for the delayed release of a physiologically active ingredient, said particles containing at least one active ingredient and a polymer matrix. The microparticles of the present invention possess particularly advantageous release characteristics. The present invention also relates to a method for manufacturing microparticles of the aforementioned kind.

  本发明涉及用于延迟释放生理活性成分的微粒，所述微粒含有至少一种活性成分和聚合物基质。本发明的微粒具有特别有利的释放特性。本发明还涉及一种制造上述微粒的方法。
• Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
  申请人：Grünenthal GmbH

  公开号：EP0856513B1

  公开（公告）日：2005-11-30
• ANTIBODY DERIVATIVES
  申请人：Allozyne, Inc.

  公开号：EP2640745A2

  公开（公告）日：2013-09-25